A phase 1/2 clinical trial showed that compared to ALL patients with KMT2A rearrangement, FLT3-mutated AML patients showed more significant advantages in overall response rate (55.5% vs. 23.1%) and overall survival (3.7 months vs. 1.4 months) [38]. Here, FLT3 is linked to acute myeloid leukemia.